Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2010.03.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Response to Kang et al, "Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study".
J Am Acad Dermatol
December 2024
The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.
Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report.
Cureus
September 2024
Hematology/Oncology, Ascension St. John Hospital, Grosse Pointe Woods, USA.
Article Synopsis
- * In a presented case, a 59-year-old woman on FOLFOX therapy experienced severe thrombocytopenia and rectal bleeding, leading to treatment adjustments and eventually identifying oxaliplatin antibodies as the cause.
- * Following the discovery of these antibodies through flow cytometry, oxaliplatin was permanently discontinued to prevent further thrombocytopenic events.
Therapeutic Effect of Superficial Scalp Hypothermia on Chemotherapy-Induced Alopecia in Breast Cancer Survivors.
J Clin Med
September 2024
Heat Pipe and Thermal Management Research Group, College of Engineering, Design and Physical Sciences, Brunel University, London UB8 3PH, UK.
Article Synopsis
- - Alopecia is a common side effect of chemotherapy for early breast cancer, with over 40% of patients experiencing permanent hair loss, impacting their body image and quality of life, leading some to refuse treatment.
- - Scalp cooling has proven to be the most effective strategy to reduce chemotherapy-induced alopecia (CIA), cutting the incidence of significant hair loss by 50% without major risks to patient survival.
- - There is a need for more research on CIA due to inconsistencies in study methods; developing standardized assessment techniques and improving preclinical models could enhance understanding and treatment options.
Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention.
Curr Oncol
September 2024
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Docetaxel is a commonly used taxane chemotherapeutic agent in the treatment of a variety of cancers, including breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, gastric cancer, and head and neck cancer. Docetaxel exerts its anti-cancer effects through inhibition of the cell cycle and induction of proapoptotic activity. However, docetaxel also impacts rapidly proliferating normal cells in the scalp hair follicles (HFs), rendering the HFs vulnerable to docetaxel-induced cell death and leading to chemotherapy-induced alopecia (CIA).
View Article and Find Full Text PDFneurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity.
Expert Opin Drug Metab Toxicol
December 2024
Experimental Neurology Unit, School of Medicine and Surgery, Monza, Italy.
Introduction: Chemotherapy induced peripheral neurotoxicity (CIPN) is a long-lasting, or even permanent, late toxicity caused by largely used anticancer drugs. CIPN affects a growing population of cancer survivors and diminishes their quality of life since there is no curative/preventive treatment. Among several reasons for this unmet clinical need, there is an incomplete knowledge on mechanisms leading to CIPN.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!